This site is intended for US Healthcare Professionals only.
MENU

Publications

Browse the library of publications below for the latest research from ADC Therapeutics scientists.

A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
View Abstract
Mechanistic studies investigating the synergistic combination of Loncastuximab Tesirine and Ibrutinib in pre-clinical models of B-cell non-Hodgkin lymphoma
View Abstract
Effect of camidanlumab tesirine (Cami) as monotherapy and in combination with pembrolizumab (PEM) on the immune cell profile in patients with selected advanced solid tumors
View Abstract
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)
View Abstract
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia Jain N, et al. Blood Adv. Feb 2020.
Download
CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy Thapa B, et al. Blood Adv. Aug 2020.
Download
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma Hamadani M, et al. Blood. Nov 2020.
Download
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Caimi PF, et al. Lancet Oncol. May 2021.
View publication
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study Hamadani M, et al. Lancet Haematol. May 2021.
View publication

Contact ADC Therapeutics

Submit a Medical Inquiry Reach out to the ADC Therapeutics team with your specific medical inquiry.
Contact Medical Affairs 1-855-690-0340
8:00 AM to 6:00 PM ET

Report Adverse Reactions or Product Complaints

To report suspected adverse events or product complaints, please call us at 1-855-690-0340 and select prompt 1. You may also call the FDA at 1-800-FDA-1088 or report suspected adverse events at www.fda.gov/medwatch.